Bioplasma
A blood-component collection system that turns the patient’s own blood into a fibrin membrane (PRF) for chronic wounds.
Fibrin membrane (PRF)
ANVISA registration
Class II
No. 82832389002
Medical device
A lesion that fails to progress toward healing in the expected time and stays open for weeks or months.
Diabetic foot ulcers, burns and traumatic injuries that do not heal.
Constant dressing changes, staff time and frequent return visits.
Infection, hospitalization and, in severe cases, amputation.
Diabetes is behind a large share of non-healing wounds and preventable amputations in the country.
16.6 M
adults with diabetes in Brazil, 6th country in the world by cases
up to 1 in 4
people with diabetes will develop a foot ulcer
10,168
diabetes-related amputations in the SUS in 2022, about 28 per day
No. 1
cause of non-traumatic lower-limb amputation
Sources: IDF Diabetes Atlas 2025, via SBD · Brazilian Ministry of Health and SBD, via Agência Brasil (2023).
PRF (Platelet-Rich Fibrin) is a concentrate obtained by centrifugation of blood alone, with no anticoagulant and no additives. Bioplasma turns this concentrate into a membrane ready to cover the wound.
No donor
Nothing synthetic
No additives
About 1 hour in total
Everything the procedure needs comes in a sterile, standardized kit, designed for the routine of outpatient clinics, health units and the bedside.
Step 01 · Collection
Venipuncture and collection into tubes without anticoagulant, at the bedside or in the outpatient clinic, using the kit’s own materials.
Step 02 · Centrifugation
The spinning force arranges the blood components by density.
Step 03 · PRF clot
The fibrin is removed with forceps and separated from the red blood cells.
Step 04 · Bioplasma device
Bioplasma shapes the clot and separates what goes onto the wound.
Cleansing of the wound bed per the team's protocol.
Using forceps, the membranes are laid in strips, side by side, covering the entire area.
Secondary dressing and reassessments per the clinical protocol.
In the literature, the PRF matrix is described as a reservoir that gradually releases platelet growth factors (such as PDGF, TGF-β and VEGF).
1 PRF session
Closure after 1 application
Age 52 · wound open for 3 months
28 days
Closure after 1 application
Age 82, hypertensive · 3 months
20 days
Closure after 1 application
37-year-old athlete
7 days
Clinical reports from the treating clinicians · Individual results, not a guaranteed timeframe.
Chronic ulcers in patients with diabetes, the main path to amputation.
Lesions that remain open, including in elderly patients with comorbidities.
Trauma wounds that need a matrix to close.
The indication for each case is determined by the clinical assessment of the responsible professional.
Everything the procedure needs comes in a sterile, standardized kit.
Sterile, disposable kit
From collection to application
Domestically manufactured
Reg. 82832389002
Bioplasma is registered with ANVISA as a Class II device. For international distribution, Novatec works in accordance with the regulatory requirements that apply to medical devices in each market.
Brazil
Class II registration · No. 82832389002
European Union
Medical Device Regulation (EU) 2017/745 — MDR
Azerbaijan
Medical devices above risk class I
Requirements apply according to the product’s risk classification in each market. The product is only imported once the applicable regulatory requirements are met.
Technical presentation of the kit to your unit or health department team.
Supervised application in a group of patients, with each case recorded.
Team training and inclusion in the wound care protocol.
Bioplasma
Moldamos o Presente para transformar o Futuro.
Navigation
© 2026 Novatec. All rights reserved. Product intended for healthcare professionals. The indication for each case is determined by the clinical assessment of the responsible professional. Individual results may vary.